News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Jan 17, 2025, 17:53

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:

“Intermittent or Continuous FOLFIRI + PANITUMUMAB RAS and BRAF Wild-Type Metastatic CRC: The IMPROVE Trial

Intermittent FOLFIRI + pani has similar outcomes in terms of PFSot and OS compared to continuous Rx. Detrimental effect in Right sided tumors.”

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Authors: Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, Giuseppe Santabarbara, Guglielmo Nasti, Vincenzo Montesarchio, Gerardo Rosati, Antonino Cassata, Silvana Leo, Carmela Romano, Emiliano Tamburini, Lucrezia Silvestro, Claudio Lotesoriere, Anna Nappi, Daniele Santini, Antonella Petrillo, Alfredo Colombo, Antonio Febbraro, Alessandra Leone, Francesco Mannavola, Maria Maddalena Laterza, Francesco Izzo, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, and Alfredo Budillon.

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

 

Akhil Santhosh Alberto Sobrero Alessandra Leone Alfonso De Stefano Alfredo Budillon Alfredo Colombo Anna Nappi Antonella Petrillo Antonino Cassata Antonio Avallone Antonio Febbraro cancer Carmela Romano Claudio Lotesoriere Daniele Santini Diana Giannarelli Emiliano Tamburini Francesco Giuliani Francesco Izzo Francesco Mannavola Gerardo Rosati Giuseppe Santabarbara Guglielmo Nasti Lucrezia Silvestro Maria Maddalena Laterza OncoDaily Oncology Paolo Delrio Silvana Leo Vincenzo Montesarchio
Special Coverage
Science
Aug 24, 2025, 12:44
Patrick Hwu: How Can We Make CAR-NK Cell Therapy More Effective Against Tough Cancers?
Societies
Aug 24, 2025, 12:40
Understanding Leptomeningeal Metastatic Disease - WeTrials
Voices
Aug 24, 2025, 12:35
FDA Begins Real-Time Reporting of Adverse Event Data
Opinion
Aug 24, 2025, 12:33
Douglas Flora: Promise of MRD Testing in GI Cancers
Voices
Aug 24, 2025, 12:08
Alique Topalian: CancerCon 2025 Opening Keynote
Insight
Aug 24, 2025, 11:58
Fawzi Abu Rous: Recent Innovative FDA Approvals in Lung Cancer
Voices
Aug 24, 2025, 11:46
Eric Bouffet: Running for Childhood Cancer Support with GFAOP on September 28
OncoDaily Pulse
Aug 24, 2025, 11:32
Yu-Wei Chen: Meet the Experts of VIRO 2025
Voices
Aug 24, 2025, 11:25
David Skorton Shared a Study on Mortality Disparities Among Women Physicians
OncoDaily Pulse
Aug 24, 2025, 11:24
Yousef Zakharia: Meet the Experts of VIRO 2025
Insight
Aug 24, 2025, 11:21
Gustave Roussy Research Shares a Study on TALAPRO-2 as a New Standard of Care in mCRPC
Voices
Aug 24, 2025, 11:15
Wafik El-Deiry Advocates for State Support of Cancer Research to Better Serve Rhode Island Communities